Navigation Links
ArterX™ Clinical Trial Results Announced at Veith Meeting
Date:11/18/2010

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York.  William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

In a presentation titled "A Novel More Effective Glue-Sealant (ArterX) for Hemostasis at Vascular Suture Lines and Other Sites," Dr. Stone reported that ArterX Surgical Sealant achieved immediate hemostasis more than 60% of the time in a 217 patient clinical trial conducted at 11 different hospitals in the US.

President and CEO, David Smith, commented, "We are delighted with the preliminary results of our US clinical trial.  We were also able to show a statistically significant reduction in operating time of 36 minutes in the ArterX group, and ArterX patients were discharged from hospital after 4.1 days, an improvement of 1.3 days over the control group. If approved, we believe that ArterX Surgical Sealant will yield economic benefits for surgeons and hospitals that adopt it."

ArterX Surgical Sealant is currently under review by the FDA and is not available for sale in the USA.

ArterX is CE Marked in the European Union

About Tenaxis Medical, Inc.

Incorporated in 2004 and located in Mountain View, CA, Tenaxis Medical, Inc. is a privately held Company. It develops novel, high performance sealants for use in vascular and general surgery. In addition to the ArterX Surgical Sealant, the company is developing a second high performance sealant for use throughout the gastrointestinal tract, and an anti-adhesion agent that can be delivered  laparoscopically to help prevent or reduce pelvic and abdominal adhesions.Contact: Ronald Dieck+1-650-691-9016, ext. 110
'/>"/>

SOURCE Tenaxis Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
2. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Clinical Experts Describe Radiosurgical Advances for Brain, Breast, and Spinal Cancers
5. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
6. PAREXEL Wins Clinical Research Team of the Year Scrip Award
7. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
10. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
Breaking Medicine Technology:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... today announced it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at ... Held at Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her childhood, ... much like a tsunami and took on a more spiritual tone. The desire to put ... do more with it than just file it away. Friends would ask her how she ...
(Date:4/28/2016)... ... ... For the 10,000 Americans who turn 65 on any given day, “getting wiser” with ... Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; Available Now)—outlines simple things ... from honing your memory and managing stress to eating healthy foods as part of ...
(Date:4/28/2016)... Boston,MA (PRWEB) , ... April 28, 2016 , ... Boston ... U.S Food and Drug Administration (FDA). The treatment consists of the application of Riboflavin, ... of the collagen fibers which in turn strengthens the cornea to slow the progression ...
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... The ... eating patterns based on the latest nutritional science. While there is a lot of ... improve their health, according to the April 2016 issue of Harvard Men's Health ...
Breaking Medicine News(10 mins):